Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Centanafadine is a once-daily norepinephrine-dopamine-serotonin reuptake inhibitor and CNS stimulant indicated for ADHD in adults and pediatric patients. Centanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant.
- Mechanism
- Curator reviewed · 2 references
Centanafadine has inhibitory activity at the norepinephrine, dopamine, and serotonin reuptake transporters and is a central nervous system stimulant. Its mechanism of action in the treatment of ADHD is unclear, but its efficacy could be mediated through its activity as a norepinephrine-dopamine-serotonin reuptake inhibitor.
- Primary indication
- Centanafadine is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older weighing at least 20 kg.Curator reviewed · 1 structured indication
- Formula / weight
- C15H15N · 209.292 g/mol (avg)
- First approval
- United States, 2026
- Code names
- EB-1020
- Brand names
- Simtriyo
Resolves to
HKHCSWPSUSWGLI-CABCVRRESA-NSMILESC1[C@@H]2CNC[C@]12C1=CC=C2C=CC=CC2=C1What you can answer from here — as of November 03, 2026
Which drugs share a target with Centanafadine, and which of those have an active Phase 3 trial?